Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Norroy Bioscience

Ownership
Private
Therapeutic Areas
Oncology
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Therapeutic radiopharmaceuticalsDiagnostic radiopharmaceuticalsRadionuclide Drug Conjugates (RDC)Chemical drugs

Norroy Bioscience General Information

Norroy Bioscience has multiple radiopharmaceutical candidates in clinical development, with three programs in Phase 2 clinical trials. Their lead candidates include 177Lu-NY108 for PSMA-Positive Prostatic Cancer, 68Ga-NY104 for Renal Cell Carcinoma, and 68Ga-NYM032 for Prostatic Cancer.

Contact Information

Website
http://www.norroybioscience.com/einfo/126.html
Primary Industry
Biotech
Corporate Office
Wuxi, Jiangsu
China

Drug Pipeline

Mortenon M1
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Norroy Bioscience's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Norroy Bioscience Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Norroy Bioscience's complete valuation and funding history, request access »

Norroy Bioscience Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals